Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Adagloxad simolenin + OBI-821|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Adagloxad simolenin||OPT-822|OBI 822|OBI822||Adagloxad simolenin (OBI-822) is an immunotherapy comprised of Globo H hexassaccharide 1 and keyhole limpet hemocyanin, which upon treatment, results in a cytotoxic T-cell response against cells expressing Globo H, and thus, may lead to antitumor activity (PMID: 32718986).|
|OBI-821||OBI821|OBI 821||OBI-821 is a natural saponin derived from the soapbark tree, Quillaja saponaria Molina, which when combined with a vaccine may help promote a cytotoxic T-cell response against tumor cells (PMID: 32718986).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03562637||Phase III||Adagloxad simolenin + OBI-821||Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC||Recruiting||USA||7|